Buy Medifast (MED) Ahead of the Analyst Meeting - DA Davidson

DA Davidson analyst Linda Bolton Weiser reiterated a Buy rating and $250.00 price target on Medifast (NYSE: MED) ahead of the July 26th convention and analyst meeting in Orlando.

The analyst stated "We expect to hear that the international product line has launched, the company is entering a new product category, and that conference attendance is up more than the 46% increase last year to 6,000. We think MED is on track to achieve its 2Q19 and 2019 guidance and that the shares are very attractive, at a new 3-year low P/E of 12.6x 2020E EPS, with targeted organic top-line growth of 25% over the next 3-4 years".

For an analyst ratings summary and ratings history on Medifast click here. For more ratings news on Medifast click here.

Shares of Medifast closed at $109.13 yesterday.

You May Also Be Interested In

• Morgan Stanley Double Downgrades AU Optronics (2409:TT) (AUO) to Underweight
• Calix (CALX) PT Lowered to $35 at Rosenblatt
• Marriott International (MAR) PT Lowered to $260 at Mizuho